Dova presented the core and extension phase study results of Doptelet (avatrombopag) in the American Society of Hematology (ASH).
The drug is approved by the US FDA for the treatment of chronic immune thrombocytopenia (ITP) in adult patients after the failure of previous treatments and in patients suffering from thrombocytopenia in adult patients with chronic liver disease.
Doptelet is an oral thrombopoietin receptor agonist. The drug has no hepatotoxicity and does not interact with the polyvalent cations.
In the Phase 3 core study, Doptelet showed superiority over placebo. The drug was superior over placebo in achieving platelet counts (PC) ≥50,000/µL, 48.6% achieved the platelet count in Doptelet ground compared with <0.01% in the placebo group. In the extension phase, platelet response achieved in 44.2 % patients in Doptelet group vs. 41.4 % in the placebo group who rolled over to AVA in the extension phase.
The company also presented the results of avatrombopag in treating thrombocytopenia in patients suffering from chronic liver disease. The company claimed that the treatment with avatrombopag resulted in a relative cost saving of USD 4,250. The company also claimed that the cost of lusutrombopag relative to avatrombopag was higher by USD 5,819.